For a diagnosis of NF1 to be made, at least two of the following symptoms should be present: Six or more CALMs, with a size greater than 5mm in children or over 15mm in adults At least one plexiform neurofibroma, which is a type of benign tumor, or any two other types of neurofibromas Freckles in the armpit or groin area, a sign indicative of NF1 Optic glioma, a type of brain tumor affecting the eyes Two or more Lisch nodules, which are benign growths on the iris of the eye A distinct bone abnormality, like abnormal bone thinning or a condition causing false joints in the bone A first-degree relative, such as a parent, sibling or child, with a diagnosis of NF1 There are other genetic syndromes associated with multiple CALMs, including Neurofibromatosis type 2 (NF2), McCune Albright Syndrome, Legius syndrome, Watson Syndrome, and Noonan syndrome with multiple lentigines (also known as LEOPARD syndrome)

Manufacturers have acknowledged that hair shedding may be related more to weight loss itself than to any toxic effect of the medication on hair follicles
Conclusion The FDAs issuance of thirty Warning Letters targeting telehealth companies marketing compounded GLP-1 drugs marks a significant escalation in the Agencys enforcement posture
Telehealth or at-home options can be more affordable when supervised remotely by a clinician and shipped to your door
Chance Miller highlighted, The affordability of blended options plays a crucial role in patient decision-making, especially when traditional medications are prohibitively expensive. Looking ahead to 2025, the market continues to reflect these pricing dynamics, with the compounded semaglutide price making combined formulations a viable alternative for those struggling with the high costs of FDA-approved drugs
It targets the learned fear and habits that keep insomnia going